...
Leadartis presenting at the AseBio Investor Day 2020
17-09-2020
Leadartis will be presenting its business proposal at the AseBio Investor Day (https://asebioevents.com/investorday/presenting-companies/) to be held on September 28-October 1st. AseBio Investor Day is the leading event allowing Spanish innovative biotechnology projects to be presented to an audience of leading international investors and pharmaceutical & industrial companies. The event is organized by AseBio, the Spanish Bioindustry Association.
LEADARTIS, THE LEADING IMMUNO-ONCOLOGY COMPANY IN SPAIN, OPENS A €1 MILLION ROUND TOGETHER WITH INVEREADY, SODENA AND CDTI INNVIERTE FOR THE DEVELOPMENT OF ITS FIRST PRODUCT IN ADVANCED CANCERS
11-09-2020
LEADARTIS, a company dedicated to the development of IMMUNO-ONCOLOGICAL medicines based on its own technology (Trimerbody®), opens a financing round of € 1M through the investment platform specialized in biomedicine, Capital Cell. The goal is to continue its research for its first third generation immuno-oncological agent against advanced cancers of the lung, breast and colon. Specifically, the forecast is to finance Phase I studies of its bispecific Trimerbody in patients with advanced or resistant cancers without a therapeutic option.
Trimerbody based therapies for COVID-19: targeting SARS-CoV-2 viral entry mechanism by next-gen trimeric Spikebodies
22-04-2020
The novel coronavirus SARS-CoV-2 has recently emerged as a human pathogen in China, causing fever, severe respiratory illness, and pneumonia a disease recently named coronavirus disease 19 (COVID-19).
LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for innovative projects focused on adding value to biomedical research. The effort wants to contribute to the discovery of drugs for diseases unmet needs, supporting the best biomedical science. Consequently, the Chemostart initiative (http://www.insudpharma.com/es/chemostart#colaboremos) is meant to promoting the best innovative projects.
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018
LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes) funded Spanish Ministry of Science, Innovation and Universities (MICINN) under the RETOS 2017 Collaboration program. ATTACK counts with collaborators such as the internationally regarded: Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid and Centro Nacional de Investigaciones Oncológicas (CNIO).
Medical oncologist Dr. Luis Paz-Ares MD, Ph.D joins Leadartis´ scientific advisory board
10-12-2018
Luis Paz-Ares MD, PhD. Chair of the Medical Oncology Department at the Hospital 12 de Octubre, Associate, Professor at the Universidad Complutense and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center) in Madrid, Spain recently has joined Leadartis´ scientific advisory board. He graduated in Medicine and completed his PhD at the Universidad Autonoma Madrid (UAM).
Nature Communications: LeadArtis outlines a new bispecific antibody that could hold the key to activate cancer killer T-cells to find and destroy highly prevalent tumors
17-11-2018
LeadArtis and collaborators have published in the highly regarded scientific journal Nature Communications a new tactic to generate a tumor-targeted bispecific antibody to target a particularly relevant immune receptor, 4-1BB, which can activate cancer killer T-cells to erradicate tumors.
Investigadores crean molécula eficaz ante el progreso de células tumorales
15-11-2018
LA VANGUARDIA
Madrid, 15 nov (EFE).- Un grupo de investigadores del Hospital 12 de Octubre de Madrid ha coordinado el diseño de una nueva molécula que reducirá la progresión de células tumorales de una forma más segura y eficaz, que supone un avance en el tratamiento con inmunoterapia que se aplicará a todo tipo de cáncer.
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018 a call for expressions of interest, focused on adding value to biomedical research from the I2D2 (Incubation Innovation in Drug Discovery) program. The foundation wanted to contribute in this way to the discovery of drugs for diseases without therapeutic solutions, supporting the best biomedical science on the mechanisms of the disease. Consequently, the I2D2 initiative is meant to promoting innovative projects.
LeadArtis presents its cancer fighting bispecific antibody programs in Seville at BioSpain 2018
29-09-2018
Leadartis has participated in BioSpain 2018 held in Seville, Spain (September, 25-27th). BioSpain, the most important biotechnology event in Spain and one of the most highly regarded internationally, was chosen to reveal the immuno-oncology (IO) antibody programs to the investment community.
Latest News
|
"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021
|
Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021
El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital... |
Leadartis to present on May 26th, 2021 its business to the 17th Annual Anglonordic Life Science Conference
20-05-2021
Anglonordic is a great event to meet quality investors and companies - it is very well run and... |
